Last reviewed · How we verify
CARTISTEM® + Debridement
CARTISTEM is an allogeneic bone marrow-derived mesenchymal stem cell product that regenerates damaged cartilage tissue when combined with surgical debridement.
CARTISTEM is an allogeneic bone marrow-derived mesenchymal stem cell product that regenerates damaged cartilage tissue when combined with surgical debridement. Used for Articular cartilage defects of the knee (Grade 3-4 chondral lesions).
At a glance
| Generic name | CARTISTEM® + Debridement |
|---|---|
| Sponsor | Medipost, Inc. |
| Drug class | Allogeneic mesenchymal stem cell therapy |
| Modality | Biologic |
| Therapeutic area | Orthopedics / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
CARTISTEM contains human mesenchymal stem cells that differentiate into chondrocytes and promote cartilage matrix regeneration. When administered following arthroscopic debridement of articular cartilage defects, the stem cells facilitate tissue repair and restore functional cartilage. The combination approach removes damaged tissue while simultaneously providing regenerative cellular therapy to promote healing.
Approved indications
- Articular cartilage defects of the knee (Grade 3-4 chondral lesions)
Common side effects
- Injection site pain or swelling
- Knee effusion
- Infection
- Immune reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CARTISTEM® + Debridement CI brief — competitive landscape report
- CARTISTEM® + Debridement updates RSS · CI watch RSS
- Medipost, Inc. portfolio CI